Andrew C Dietz1, Giovanna Lucchini, Sujith Samarasinghe, Michael A Pulsipher. 1. aChildren's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, USA bDepartment of Paediatric Bone Marrow Transplant cDepartment of Paediatric Haematology, Great Ormond Street Hospital, London, UK *Andrew C. Dietz and Giovanna Lucchini contributed equally to the writing of this article.
Abstract
PURPOSE OF REVIEW: Significant improvements in unrelated donor hematopoietic stem cell transplantation (HSCT) in recent years have solidified its therapeutic role in severe aplastic anemia (SAA) and led to the evolution of treatment algorithms, particularly for children. RECENT FINDINGS: Advances in understanding the genetics of inherited bone marrow failure syndromes (IBMFS) have allowed more confidence in accurately diagnosing SAA and avoiding treatments that could be dangerous and ineffective in individuals with IBMFS, which can be diagnosed in 10-20% of children presenting with a picture of SAA. Additionally long-term survival after matched sibling donor and matched unrelated donor HSCT now exceed 90% in children. Late effects after HSCT for SAA are minimal with current strategies, and compare favorably to late effects after upfront immunosuppressive therapy, except for patients with chronic graft versus host disease. SUMMARY: Careful assessment for signs or symptoms of IBMFS, along with genetic screening for these disorders, is of major importance. Matched sibling donor HSCT is already considered the standard of care for upfront therapy and some groups are evaluating matched unrelated donor HSCT as primary therapy. Ongoing studies will continue to challenge treatment algorithms and may lead to an even more expanded role for HSCT in SAA.
PURPOSE OF REVIEW: Significant improvements in unrelated donor hematopoietic stem cell transplantation (HSCT) in recent years have solidified its therapeutic role in severe aplastic anemia (SAA) and led to the evolution of treatment algorithms, particularly for children. RECENT FINDINGS: Advances in understanding the genetics of inherited bone marrow failure syndromes (IBMFS) have allowed more confidence in accurately diagnosing SAA and avoiding treatments that could be dangerous and ineffective in individuals with IBMFS, which can be diagnosed in 10-20% of children presenting with a picture of SAA. Additionally long-term survival after matched sibling donor and matched unrelated donor HSCT now exceed 90% in children. Late effects after HSCT for SAA are minimal with current strategies, and compare favorably to late effects after upfront immunosuppressive therapy, except for patients with chronic graft versus host disease. SUMMARY: Careful assessment for signs or symptoms of IBMFS, along with genetic screening for these disorders, is of major importance. Matched sibling donor HSCT is already considered the standard of care for upfront therapy and some groups are evaluating matched unrelated donor HSCT as primary therapy. Ongoing studies will continue to challenge treatment algorithms and may lead to an even more expanded role for HSCT in SAA.
Authors: Roland Chu; Ruta Brazauskas; Fangyu Kan; Asad Bashey; Christopher Bredeson; Bruce Camitta; Kuang-Yueh Chiang; Haydar Frangoul; Robert Peter Gale; Adrian Gee; Biju George; Frederick D Goldman; Thomas G Gross; Vikas Gupta; Gregory A Hale; Luis Isola; Alvaro Urbano Ispizua; Hillard Lazarus; Judith Marsh; James Russell; Mitchell Sabloff; Edmund K Waller; Mary Eapen Journal: Biol Blood Marrow Transplant Date: 2010-10-27 Impact factor: 5.742
Authors: A Bacigalupo; F Locatelli; E Lanino; J Marsh; G Socié; S Maury; A Prete; A Locasciulli; S Cesaro; J Passweg Journal: Bone Marrow Transplant Date: 2005-12 Impact factor: 5.483
Authors: Michael Y Zhang; Siobán B Keel; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Amanda C Watts; Colin C Pritchard; Stephen J Salipante; Michael R Jeng; Inga Hofmann; David A Williams; Mark D Fleming; Janis L Abkowitz; Mary-Claire King; Akiko Shimamura Journal: Haematologica Date: 2014-09-19 Impact factor: 9.941
Authors: I Esteves; C Bonfim; R Pasquini; V Funke; N F Pereira; V Rocha; Y Novis; C Arrais; V Colturato; M P de Souza; M Torres; J F Fernandes; F R Kerbauy; A A F Ribeiro; F P S Santos; N Hamerschlak Journal: Bone Marrow Transplant Date: 2015-03-02 Impact factor: 5.483
Authors: Andrea Bacigalupo; Gerard Socié; Rose Marie Hamladji; Mahmoud Aljurf; Alexei Maschan; Slawomira Kyrcz-Krzemien; Alicja Cybicka; Henrik Sengelov; Ali Unal; Dietrich Beelen; Anna Locasciulli; Carlo Dufour; Jakob R Passweg; Rosi Oneto; Alessio Signori; Judith C W Marsh Journal: Haematologica Date: 2015-01-23 Impact factor: 9.941
Authors: Paola Saracco; Paola Quarello; Anna Paola Iori; Marco Zecca; Daniela Longoni; Johanna Svahn; Stefania Varotto; Gian Carlo Del Vecchio; Carlo Dufour; Ugo Ramenghi; Andrea Bacigalupo; Anna Locasciulli Journal: Br J Haematol Date: 2008-01 Impact factor: 6.998
Authors: J C Marsh; R M Pearce; M B C Koh; Z Lim; A Pagliuca; G J Mufti; J Perry; J A Snowden; A J Vora; R T Wynn; N Russell; B Gibson; M Gilleece; D Milligan; P Veys; S Samarasinghe; M McMullin; K Kirkland; G Cook Journal: Bone Marrow Transplant Date: 2013-08-05 Impact factor: 5.483
Authors: Austin G Armstrong; Bruce F Kimler; Brigid M Smith; Teresa K Woodruff; Mary Ellen Pavone; Francesca E Duncan Journal: Future Oncol Date: 2018-01-18 Impact factor: 3.404
Authors: Wu Yamei; Luo Rongmu; Cao Yongbin; Si Yingjian; Li Xiaohong; Zhang Xiaomei; Yan Pei; Du Zhenlan; Wang Haitao; Wang Jing; Wang Bojing; Wu Xiaoxiong; Da Wanming Journal: Oncotarget Date: 2017-07-31
Authors: E Ilker Ozay; Jyothi Vijayaraghavan; Gabriela Gonzalez-Perez; Sudarvili Shanthalingam; Heather L Sherman; Daniel T Garrigan; Karthik Chandiran; Joe A Torres; Barbara A Osborne; Gregory N Tew; Igor I Slukvin; Ross A Macdonald; Kilian Kelly; Lisa M Minter Journal: Stem Cell Res Date: 2019-02-01 Impact factor: 2.020